Showing 1451-1460 of 5062 results for "".
- Lutronic Rolls Out Derma V Dermatology Platformhttps://practicaldermatology.com/news/lutronic-rolls-out-derma-v-dermatology-platform/2460972/Lutronic is launching Derma V, a dermatology workstation that comprises a 532nm green laser, a 1064nm laser plus ICD cooling and IntelliTrack. "We created a device that brings the essential lasers that skin specialists need for their daily work - vascular, pigment and rejuvenation
- Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/castle-creek-biosciences-awarded-fda-orphan-products-development-grant-to-support-phase-3-study-of-fcx-007-investigational-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2460966/The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development awarded Castle Creek Biosciences a $1.825 million research grant to support the Phase 3 development program of the investigational gene therapy FCX-007 for treatment of recessive dystrophic epide
- Vivacare Partnership with Asthma and Allergy Network Provides Professional Digital Patient Education Servicehttps://practicaldermatology.com/news/vivacare-partnership-with-asthma-and-allergy-network-provides-professional-digital-patient-education-service/2460956/Through a new partnership, Vivacare and the Asthma and Allergy Network (AAN) will provide a digital patient education service to Vivacare’s 18,000 professional members, including allergists, dermatologists, pediatricians and primary care providers. Personalized “P
- Link Between Melanoma and Estrogen May Lead to New Therapeutic Approachhttps://practicaldermatology.com/news/link-between-melanoma-and-estrogen-may-lead-to-new-therapeutic-approach/2460953/The link between estrogens and breast cancer has long been defined, but a Duke-led research team has identified how these hormones can also influence the growth of other cancers, notably melanoma.
- Aveeno Launches #SkinVisibility Campaignhttps://practicaldermatology.com/news/aveeno-launches-skinvisibility-campaign/2460948/Aveeno’s new #SkinVisibility campaign aims to address the underdiagnosis, care and treatment of eczema on Black skin. The campaign, which launches during Eczema Awareness Month, underscores the brand's pledge to help 100,000 people with eczema find relief&n
- Safety Concerns Fuel Vaccine Hesitancy in PsO Patients on Biologics, But Data Fail to Show Increased Riskhttps://practicaldermatology.com/news/safety-concerns-fuel-vaccine-hesitancy-in-pso-patients-on-biologics-but-data-fail-to-show-increased-risk/2460947/Safety concerns and concerns about aggravation of their underlying condition are common drivers of COVID-19 vaccine hesitancy among patients with psoriatic disease, results of a new study show. Data come from an analysis of social media posts from patients in the US, UK, France, Germany, and
- PsO Improves Among Patients Who Switch to Janssen's Tremfya from Adalimumabhttps://practicaldermatology.com/news/pso-improves-among-patients-who-switch-to-janssens-tremfya-from-adalimumab/2460940/A total of 19 abstracts at the European Academy of Dermatology Venereology 30th Anniversary Congress will present data for Janssen’s Tremfya (guselkumab), including data showing an improvement in PASI response for psoriasis (PsO
- Updates from EADV: Cosentyx Autoinjector, Genetic Variants Linked to Genital Warts, At-Home PDT Shows Promisehttps://practicaldermatology.com/news/updates-from-eadv-cosentyx-autoinjector-genetic-variants-linked-to-genital-warts-at-home-pdt-shows-promise/2460939/• Treatment with Cosentyx®(secukinumab) 300mg in a 2mL autoinjector (UnoReady® pen) was more effective than placebo and achieved high patient satisfaction compared to two 150mg pre-filled syringes, according to Phase 3b data presented
- No Concerning Safety Signals for Timber's Topical Isotretinoin in Congenital Ichthyosishttps://practicaldermatology.com/news/no-concerning-safety-signals-for-timbers-topical-isotretinoin-in-congenital-ichthyosis/2460934/Phase 2a study results demonstrate no concerning safety signals and no evidence of significant systemic exposure to isotretinoin or tretinoin after 12 weeks of treatment with Timber Pharmaceuticals’ topical isotretinoin formulation (TMB-001) in pa
- Bimekizumab Performs Well in Psoriasis with Results Lasting through Two Yearshttps://practicaldermatology.com/news/bimekizumab-performs-well-in-psoriasis-with-results-lasting-through-two-years/2460929/Interim results from the BE BRIGHT open-label extension (OLE) study showed clinical responses observed in bimekizumab-treated psoriasis patients during the first 16 weeks of BE SURE were sustained through to two years of treatment with continuous maintenance dosing, UCB reports. T